SCHEMBL1749800

SCHEMBL1749800

CC(=O)CNC1CCN(c2ccc(NC(=O)Cc3ccc(-c4ccc(F)cc4)cc3)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.56
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
MCL1 Q07820 1/20 0.49
GAA P10253 3/20 0.48
CYP2D6 P10635 1/20 0.47
CHRM1 P11229 1/20 0.47
HTR2A P28223 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
REV1 Q9UBZ9 1/20 0.45
MAPT P10636 4/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NR4A1 P22736 1/20 0.43
LMNA P02545 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750755 0.91 MCHR1 (0.68) MCHR1NPC1RAB9AMCL1SMN1; SMN2
SCHEMBL1751085 0.88 NPC1 (0.53) MCHR1NPC1RAB9AMCL1GAA
SCHEMBL1749074 0.85 NPC1 (0.50) MCHR1NPC1RAB9AMCL1GAA
SCHEMBL1749502 0.83 NPC1 (0.55) MCHR1NPC1RAB9AMCL1GAA
SCHEMBL1749023 0.82 MAPT (0.49) MCHR1NPC1RAB9AMCL1GAA
SCHEMBL1749177 0.82 MAPT (0.49) MCHR1NPC1RAB9AMCL1GAA
SCHEMBL1749801 0.82 MCHR1 (0.71) MCHR1NPC1RAB9AMCL1GAA
SCHEMBL1749574 0.81 MCHR1 (0.47) MCHR1NPC1RAB9AMCL1GAA
SCHEMBL12529280 0.81 MCHR1 (0.83) MCHR1NPC1RAB9AMCL1GAA
SCHEMBL1749465 0.81 RAB9A (0.55) MCHR1NPC1RAB9AMCL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 MCHR1 2068/4885NPC1 1718/4885RAB9A 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.